CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today announced that members of the management team will present at the following upcoming investor conferences:
• The Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016, at 10:00 a.m. ET at the Boston Marriott Copley Place in Boston.
